Abus.Am

ABUS.AM has a liquidity position that is characterized by a current ratio of 1.42, indicating that the company has sufficient current assets to cover its current liabilities, albeit with limited excess. The company's liquidity is assessed as medium, with a key flag indicating that net cash is negative after subtracting total debt. The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.3, suggesting that it is not heavily leveraged.

In terms of profitability, ABUS.AM reported a net income of -1,109,310, indicating a net loss for the period. The company's return on equity is -9.88%, and its return on assets is -2.57%, both of which are negative and suggest that the company is not generating returns that exceed its cost of capital. These metrics are below the industry median for the passenger transportation, ground and sea sector, indicating that the company is underperforming its peers in terms of profitability and returns.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements. There is no significant geographic diversification, and the company's exposure is primarily to the local market. This concentration could pose a risk if the local market experiences a downturn or if the company's primary transportation services face regulatory or operational challenges.

ABUS.AM's growth trajectory is uncertain, as the company reported a net loss and negative returns on equity and assets. The company's capital expenditure for the period was -41,750, indicating a reduction in investment in long-term assets. This could be a sign of cost-cutting measures or a strategic shift in the company's capital allocation. The outlook for the company's revenue and profitability is not provided in the available data, but the current financial performance suggests a challenging environment.

The company's risk assessment indicates a medium liquidity risk, with a key flag noting that net cash is negative after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential identified. The company's financial structure and performance suggest that it may face challenges in maintaining its liquidity and profitability, particularly if the transportation market experiences a downturn.

Recent events and filings do not provide specific details on the company's strategic initiatives or operational changes. The company's financial statements and risk assessment suggest that it is operating in a challenging environment, with a need to improve its profitability and manage its liquidity effectively. The company's performance and risk profile indicate that it may require strategic adjustments to enhance its financial stability and growth prospects.

Arbutus Biopharma maintains a zero debt-to-equity ratio, significantly reducing financial leverage risk compared to the pharmaceutical cohort median.

The company holds a strong current ratio of 15.73, indicating robust short-term liquidity and minimal immediate solvency concerns.

Analysts assign a mean price target of $5.17, suggesting approximately 9% upside potential from the current market price of $4.74.

Operating losses narrowed significantly in FY2025 to $38.2 million, reflecting improved cost management compared to prior fiscal periods.

Cash conversion metrics rank above the cohort median, suggesting relatively efficient capital deployment within the pharmaceutical sector.

The company generated negative free cash flow of $39.6 million in FY2025, continuing its pattern of cash burn.

Operating and net margins rank in the bottom quartile of the pharmaceutical cohort, indicating poor profitability relative to peers.

Revenue CAGR of -41.7% over two years highlights a persistent and accelerating decline in business scale.